Abstracts Archive - Page 805 of 2425 - ACR Meeting Abstracts

Abstract Number: 191 • 2020 Pediatric Rheumatology Symposium
Utilization of Telemedicine in Pediatric Rheumatologic Care
Rajdeep Pooni¹ and Tzielan Lee ¹, ¹Stanford Children's, Palo Alto
Background/Purpose: Telemedicine has the potential for improving access to care, particularly for pediatric patients with complex needs in remote or rural locations. Previous studies have…
Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
Stephen Wong¹, Amy Gaultney ² and Deborah McCurdy ³, ¹University of California Los Angeles, Los Angeles, California, ²UCLA, Los Angeles, California, ³UCLA Medical Center, Los Angeles, California
Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…
Abstract Number: 193 • 2020 Pediatric Rheumatology Symposium
Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE
Kiana Johnson¹, Anna Richmond ² and Kathleen O'Neil ³, ¹East Tennessee State University, Johnson City, ²Nashville, ³University of Indiana School of Medicine, Indianapolis, Indiana
Background/Purpose: Especially important in the transition process is the role of the providers and parents and providers shifting from that of a manager of health…
Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L03 • 2019 ACR/ARP Annual Meeting
NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia
Steven Harte ¹, Leslie Arnold ², Eric Ichesco ¹, Christopher Crumb ¹, Mary Suh ³, Laurel Sindelar ³, Chelsea Kaplan ¹, Tony Larkin ¹, Andrew Schrepf ¹, Daniel Clauw ⁴, Stephen Sainati ³ and Richard Harris¹, ¹University of Michigan, Ann Arbor, ²University of Cincinnati College of Medicine, Cincinnati, ³Aptinyx Inc, Evanston, ⁴Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating disease typified by widespread musculoskeletal pain and accompanied by fatigue, sleep disturbance, memory issues, and mood disorders. FM…
Abstract Number: L04 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Maaman Bashir¹, Katherine Sherman ², Sara K. Tedeschi ³ and Ann Rosenthal ¹, ¹Medical College of Wisconsin, Milwaukee, ²Milwaukee VAMC, Milwaukee, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Benjamin Hsu¹, Jennifer Visich ², Mark Genovese ³, Kimberly Walter ², Mahru An ⁴, Remi-Martin Laberge ⁴ and Jamie Dananberg ⁴, ¹Unity Biotechnology, Brisbane, ²Unity Biotechnology, Brisbane, California, ³Stanford University, Stanford, CA, ⁴Unity Biotechnology, Brisbane, CA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
Abstract Number: L06 • 2019 ACR/ARP Annual Meeting
Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids
Fabrizio De Benedetti¹, Paul Brogan ², Alexei A. Grom ³, Pierre Quartier ⁴, Rayfel Schneider ⁵, Jordi Antón ⁶, Claudia Bracaglia ⁷, Manuela Pardeo ⁸, Giulia Marucci ⁸, Emanuela Sacco ⁹, Despina Eleftheriou ¹⁰, Charalampia Papadopoulou ¹¹, Philippe Jacqmin ¹², maria ballabio ¹³ and Cristina de Min ¹³, ¹Bambino Gesù Children's Hospital, Rome, Italy, ²Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Necker Hospital, Paris, France, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁸Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, ¹⁰UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section,, london, United Kingdom, ¹¹UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology section, london, United Kingdom, ¹²MnS, Dinant, Belgium, ¹³Sobi AG, basel, Switzerland
Background/Purpose: MAS is a severe complication of rheumatic diseases, most frequently sJIA and adult-onset Still’s disease. It is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias,…
Abstract Number: L07 • 2019 ACR/ARP Annual Meeting
A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis
Liam O'Neil¹, Victor Spicer ¹, Irene Smolik ¹, Xiaobo Meng ¹, John Wilkins ¹ and Hani El-Gabalawy ², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are currently the primary biomarker for identifying individuals at increased risk for future RA development. However, we have recently shown…
Abstract Number: L08 • 2019 ACR/ARP Annual Meeting
Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial
Siri Lillegraven¹, Nina Sundlisater ², Anna-Birgitte Aga ³, Joe Sexton ¹, Inge Christoffer Olsen ⁴, Hallvard Fremstad ⁵, Cristina Spada ⁶, Tor Magne Madland ⁷, Christian Høili ⁸, Gunnstein Bakland ⁹, Åse Lexberg ¹⁰, Inger Johanne Widding Hansen ¹¹, Inger Myrnes Hansen ¹², Hilde Haukeland ¹³, Maud-Kristine Aga Ljoså ¹⁴, Ellen Moholt ¹⁵, Till Uhlig ¹⁶, Daniel Solomon ¹⁷, Désirée van der Heijde ¹⁸, Tore Kvien ¹⁶ and Espen A Haavardsholm ¹⁵, ¹Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, ⁶Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, ⁷Haukeland University Hospital, Bergen, Norway, ⁸Hospital Østfold HF, Moss, Norway, ⁹University Hospital of North Norway, Tromsø, Norway, ¹⁰Drammen Hospital, Vestre Viken HF, Drammen, Norway, ¹¹Sørlandet Hospital HF, Kristiansand, Norway, ¹²Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹³Martina Hansens Hospital, Bærum, Norway, ¹⁴Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, ¹⁵Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ¹⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
Abstract Number: L09 • 2019 ACR/ARP Annual Meeting
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial
Merete Lund Hetland¹, Espen A Haavardsholm ², Anna Rudin ³, Dan Nordström ⁴, Mike Nurmohamed ⁵, Bjorn Gudbjornsson ⁶, Jon Lampa ⁷, Kim Hørslev-Petersen ⁸, Till Uhlig ⁹, Gerdur Grondal ¹⁰, Mikkel Østergaard ¹¹, Marte Heiberg ², Jos Twisk ¹², Kristina Lend ⁷, Simon Krabbe ¹³, Joakim Lindqvist ⁷, Anna-Karin Ekwall ¹⁴, Kathrine Lederballe Grøn ¹⁵, Meliha Kapetanovic ¹⁶, Francesca Faustini ⁷, Riitta Tuompo ¹⁷, Tove Lorenzen ¹⁸, Giovanni Cagnotto ¹⁹, Eva Baecklund ²⁰, Oliver Hendricks ²¹, Daisy Vedder ²², Tuulikki Sokka-isler ²³, Tomas Husmark ²⁴, Maud-Kristine Aga Ljoså ²⁵, Eli Brodin ²⁶, Torkell Ellingsen ²⁷, Annika Söderbergh ²⁸, Milad Rizk ²⁹, Åsa Reckner ³⁰, Line Uhrenholt ³¹, Per Larsson ³², Soeren Just ³³, David Stevens ³⁴, Trine Laurberg ³⁵, Gunnstein Bakland ³⁶, Inge Christoffer Olsen ³⁷, Ronald van Vollenhoven ³⁸ and The NORD-STAR Study Group ³⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Diakonhjemmet Hospital, Oslo, Norway, ³Dept Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden, ⁴Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁵Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Department of Rheumatology, King Christian X's Hospital for Rheumatic Diseases Graasten, Denmark, Graasten, Denmark, ⁹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹⁰Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ¹¹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ¹²Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, Netherlands, ¹³Rigshospitalet, København, Denmark, ¹⁴University of Gothenburg, Kullavik, Sweden, ¹⁵Rigshospitalt Glostrup, Glostrup, Denmark, ¹⁶Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ¹⁷Helsinki University Hospital, Helsinki, Finland, ¹⁸Reumatologi, Regionshospitalet Silkeborg, Kolding, Denmark, ¹⁹Lund University, Malmö, Sweden, ²⁰Uppsala University, Uppsala, Sweden, ²¹Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²²Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, ²³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²⁴Rheumatology Clinic, Falun, Sweden, ²⁵Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Department of Rheumatology, Odense University Hospital, Denmark, Odense, Syddanmark, Denmark, ²⁸Örebro University Hospital, Ôrebro, Sweden, ²⁹Västmanlands Hospital, Västerås, Sweden, ³⁰Rheumatology Department, Linkoping, Sweden, ³¹Aalborg Universitetshospital, Aalborg, Denmark, ³²Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³³Odense University Hospital, Odense, ³⁴St. Olav's University Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway, ³⁸Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, ³⁹Site investigators in all participating countries, Stockholm, Sweden
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…
Abstract Number: L10 • 2019 ACR/ARP Annual Meeting
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Roberta Gualtierotti¹, Francesca Ingegnoli ², Massimo Boscolo ³, Samantha Griffini ³, Elena Grovetti ⁴ and Massimo Cugno ⁵, ¹Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Lombardia, Italy, ²UOC Reumatologia Clinica, ASST Pini-CTO, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy, ³Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Italy, Milan, ⁴Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Milan, ⁵Medicina Interna, Ospedale Maggiore Policlinico, IRCCS Fondazione Ca' Granda Milano, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease associated with a prothrombotic state. Tocilizumab, an interleukin-6 receptor inhibitor, is highly effective in controlling…
Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Thomas W.J. Huizinga ⁴, Gustavo Citera ⁵, Clifton Bingham ⁶, Subhashis Banerjee ⁷, Benjamin Soule ⁸, Marleen Nys ⁹, Sean Connolly ¹⁰, Robert Wong ¹⁰, Kuan-Hsiang Gary Huang ⁷ and Roy Fleischmann ¹¹, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁶Johns Hopkins University, Baltimore, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Bristol-Myers Squibb, Princeton, New Jersey, ⁹Bristol-Myers Squibb, Braine L'Alleud, Belgium, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].